NCT03667417 Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation
| NCT ID | NCT03667417 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Paoli-Calmettes |
| Condition | Breast Cancers |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 1999-10-15 |
| Primary Completion | 2028-10-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 1999-10-15 with a primary completion date of 2028-10-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cohort of subjects carrying a BRCA gene mutation: genetic predispositions to breast and ovarian cancers
Eligibility Criteria
1. Woman or man, with or without cancer, carrying a deleterious BRCA1/BRCA2 mutation, aged 18 years and over. 1. Woman with or without breast cancer or ovarian cancer at baseline. 2. Man with or without breast cancer at baseline. 2. Signed consent to participation 3. Affiliation to a social security regimen, or beneficiary of such a regimen. Exclusion Criteria: 1. A person of legal age subject to a legal protection measure, or unable to express consent. 2. Impossibility to submit to the follow-up of the test for geographical, social or psychological reasons
Contact & Investigator
Catherine NOGUES, MD
PRINCIPAL INVESTIGATOR
Institut Paoli-Calmettes
Frequently Asked Questions
Who can join the NCT03667417 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03667417 currently recruiting?
Yes, NCT03667417 is actively recruiting participants. Contact the research team at DRCI.UP@ipc.unicancer.fr for enrollment information.
Where is the NCT03667417 trial being conducted?
This trial is being conducted at Marseille, France.
Who is sponsoring the NCT03667417 clinical trial?
NCT03667417 is sponsored by Institut Paoli-Calmettes. The principal investigator is Catherine NOGUES, MD at Institut Paoli-Calmettes. The trial plans to enroll 5,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.